Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems
Summary
Amit Vohra, Founder and CEO of Promaxo, expressed his enthusiasm: "We are thrilled to partner with Zynext Ventures and leverage their extensive expertise in the healthcare sector. Headquartered in Pennington, NJ, Zynext seeks to support and catalyze the development of groundbreaking technologies with the potential to solve unmet healthcare needs. The group employs 26,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. Based in Oakland, California, and backed by over 200 patents, the Companys mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities.